NCT07302607Recruiting
Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021
Source: ClinicalTrials.gov · Last updated 24 Dec 2025
Brief summary (registry, in English)
Although impressive progress has been made with this new therapeutic strategy, only a proportion of patients achieve a complete and sustained response. Studies have already identified predictive factors of treatment response that are now widely recognized. In this study, the investigators aim to identify other response factors not yet evaluated in the literature.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 221 (estimated)
- First submitted
- 10 Dec 2025
- Start date
- 11 Dec 2024
- Primary completion date
- Jan 2026
- Lead sponsor
- University Hospital, Strasbourg, France
- Diseases
- Melanoma
- NCT number
- NCT07302607
What you commit to
- Study type: Observational
- Planned participants: 221
- From 11 Dec 2024 to the primary completion date, Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Adjuvant-intent immunotherapy;
- Less than 3 months of follow-up after the start of immunotherapy;
Other
- Primary choroidal melanoma;
- Change of treatment before the first reassessment;
- Treatment and follow-up at a department other than the Dermatology Department of the Strasbourg University Hospitals.
Who the study is looking for
- Age ≥ 18 years;
- Unresectable stage III or stage IV melanoma according to the AJCC classification - 8th edition;
- Curative immunotherapy treatment (anti-PD-1 and/or anti-CTLA-4);
- Treatment and follow-up at the Dermatology Department of the Strasbourg University Hospitals;
- Immunotherapy initiated between January 1, 2013, and December 31, 2021.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Service de dermatologie - Réanimation - CHU de Strasbourg - France Coordinator of this site? Confirm its status | Strasbourg | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.